Small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other malignant tumors
Conditions
Interventions
Gold Standard:Tumor pathology diagnosis or follow-up results, and 18F-FDG PET imaging
Index test:One hour after a single intravenous injection of 18F-FDG (approximately 185 +/- 37 MBq) via the dorsal hand vein on the first day of examination, PET imaging was performed. After an overnig
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.The subject or their legal representative is permitted to sign the informed consent form. 2.The subject has committed themselves to adherence to the prescribed research procedures and to cooperation in the implementation of the entire study process. 3.Adult patients (aged 18 years or older), irrespective of gender; 4.Patients with a clinical suspicion or confirmed diagnosis of small cell lung cancer, breast cancer, nasopharyngeal carcinoma, and other tumours (for which supporting evidence is provided in the form of serum-related tumour markers, ultrasound, CT, MRI and other image data, and histopathological examination); 5.The patient is generally in good condition; 6.It is mutually agreed upon by all parties involved that the designated specimen shall be utilised for the purposes of this study.
Exclusion criteria
Exclusion criteria: 1. The patient or their legal representative is unable or unwilling to sign the informed consent form; 2. The patient is unable to cooperate with the entire study procedure; 3. Acute systemic disease or electrolyte imbalance; 4. Pregnancy or lactation; 5. Other conditions deemed unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax of lesions on 68Ga-FL-031 and 18F-FDG PET;Tumor to background ratio (TBR);SUVmean of lesions in the descending aorta for 68Ga-FL-031 and 18F-FDG.;SUVmean of lesions in the right hepatic lobe for 68Ga-FL-031 and 18F-FDG.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Expression content of SSTR2 targets in lesions; | — |
Countries
China
Contacts
Public ContactLan Xiaoli
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed